Drug Database · Clinicians

C + Meningococcal group a + W-135 + Y conjugate vaccine

Brands (1) MenquadfiShow all

Vaccines PH FDA category
Fixed-dose combination.

Rx · Prescription drug1 PH product
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: EU Summary of Product Characteristics (EMA), Menveo, revised October 14, 2025, reproduced with acknowledgment of the source (EPAR page · product information (PDF)). Marketing authorization holder: GSK Vaccines S.r.l.. Text is quoted verbatim, in the original British spelling. This generic has no US FDA label. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

SmPC 4.1 Therapeutic indications EU SmPC (EMA)

Menveo is indicated for active immunization of children (from 2 years of age), adolescents and adults at risk of exposure to Neisseria meningitidis groups A, C, W-135 and Y, to prevent invasive disease. The use of this vaccine should be in accordance with official recommendations.

Contraindications

SmPC 4.3 Contraindications EU SmPC (EMA)

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1, or diphtheria toxoid (CRM197), or a life-threatening reaction after previous administration of a vaccine containing similar components (see section 4.4).

As with other vaccines, Menveo should be postponed in individuals suffering from an acute severe febrile illness. The presence of a minor infection is not a contraindication.

Dosing: Adult

SmPC 4.2 Posology and method of administration EU SmPC (EMA)

Posology

Children (from 2 years of age), adolescents and adults

Menveo should be administered as a single dose (0.5 mL). To ensure optimal antibody levels against all vaccine serogroups, the primary vaccination schedule with Menveo should be completed one month prior to risk of exposure to Neisseria meningitidis groups A, C, W-135 and Y. Bactericidal antibodies (hSBA ≥ 1:8) were observed in at least 64% of subjects at 1 week post vaccination (see section 5.1 for immunogenicity data per individual serogroups).

Older adults and elderly

There are limited data in older adults (aged 56-65 years) and there are no data in elderly (aged > 65 years).

Booster vaccination

Long-term antibody persistence data following vaccination with Menveo are available up to 5 years after vaccination (see section 4.4 and 5.1).

Menveo may be given as a booster dose in subjects who have previously received primary vaccination with Menveo, other conjugated meningococcal vaccine or meningococcal unconjugated polysaccharide vaccine. The need for and timing of a booster dose in subjects previously vaccinated with Menveo is to be defined based on national recommendations.

Paediatric population (under 2 years of age)

The safety and efficacy of Menveo in children under 2 years of age has not yet been established. Currently available data are described in section 5.1 but no recommendation on a posology can be made.

Method of administration

Menveo is given as an intramuscular injection, preferably into the deltoid muscle. It must not be administered intravascularly, subcutaneously or intradermally.

Separate injection sites must be used if more than one vaccine is being administered at the same time.

For instructions on preparation of the medicinal product before administration, see section 6.6.

Dosing: Altered kidney function

The EU SmPC (EMA) for this generic has no separate kidney-specific text. See SmPC 4.2 and 5.2 below, and the Philippine package insert.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric population (SmPC 4.2) EU SmPC (EMA)

Children (from 2 years of age), adolescents and adults

Menveo should be administered as a single dose (0.5 mL). To ensure optimal antibody levels against all vaccine serogroups, the primary vaccination schedule with Menveo should be completed one month prior to risk of exposure to Neisseria meningitidis groups A, C, W-135 and Y. Bactericidal antibodies (hSBA ≥ 1:8) were observed in at least 64% of subjects at 1 week post vaccination (see section 5.1 for immunogenicity data per individual serogroups).

Paediatric population (under 2 years of age)

The safety and efficacy of Menveo in children under 2 years of age has not yet been established. Currently available data are described in section 5.1 but no recommendation on a posology can be made.

Dosing: Older adult

Older adults (SmPC 4.2) EU SmPC (EMA)

Older adults and elderly

There are limited data in older adults (aged 56-65 years) and there are no data in elderly (aged > 65 years).

Dosage forms

Registered products in the Philippines

1 product registered with the Food and Drug Administration (FDA) Philippines list C + Meningococcal group a + W-135 + Y conjugate vaccine as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

Philippine FDA-registered products for C + Meningococcal group a + W-135 + Y conjugate vaccine
Package insert
MenquadfiMeningococcal Group A, C, W-135 and Y Conjugate Vaccine
Formulation: Each dose (0.5 mL) contains: Neisseria meningitidis group A polysaccharide* .... 10 mcg Neisseria meningitidis group C polysaccharide* .... 10 mcg Neisseria meningitidis group Y polysaccharide* .... 10 mcg Neisseria meningitidis group W-135 polysaccharide* .... 10 mcg *Conjugated to Tetanus Toxoid carrier protein... 55 mcg** **Tetanus Toxoid quantity is approximate and dependent on the polysaccharide to protein ratio for the conjugates in each formulation Solution for Injection (IM)Single dose. 0.5 mL in 2 mL USP Type I glass vial with gray chlorobutyl rubber stopper sealed with aluminum and black plastic flip-off cap (Box of 1's and 5's)
Rx
Sanofi PasteurU.S.A
Zuellig Pharma CorporationImporter: Sanofi Pasteur, Inc.
BR-1388
Mar 4, 2027

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Warnings/Precautions

SmPC 4.4 Special warnings and precautions for use EU SmPC (EMA)

Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

Hypersensitivity and anaphylaxis

Before the injection of any vaccine, the person responsible for administration must take all precautions known for the prevention of allergic or any other reactions including thorough medical history and current health status. As with all injectable vaccines, appropriate medical treatment and supervision must always be readily available in case of a rare anaphylactic event following administration of the vaccine.

Anxiety-related reactions

Anxiety‐related reactions, including vasovagal reactions (syncope), hyperventilation or stress‐related reactions may occur in association with vaccination as a psychogenic response to the needle injection (see section 4.8). It is important that procedures are in place to avoid injury from fainting.

Menveo should under no circumstances be administered intravascularly.

Limitations of effectiveness

Menveo will not protect against infections caused by any other serogroups of N. meningitidis not present in the vaccine.

As with any vaccine, a protective immune response may not be elicited in all vaccinees (see section 5.1).

Studies with Menveo have shown a waning of serum bactericidal antibody titers against serogroup A when using human complement in the assay (hSBA) (see section 5.1). The clinical relevance of the waning of hSBA serogroup A antibody titers is unknown. If an individual is expected to be at particular risk of exposure to Men-A and received a dose of Menveo more than approximately one year previously, consideration may be given to administering a booster dose.

There are no data on the applicability of the vaccine for post-exposure prophylaxis.

Immunocompromised individuals

In immunocompromised individuals, vaccination may not result in an appropriate protective antibody response. While Human Immunodeficiency Virus (HIV) infection is not a contraindication, Menveo has not been specifically evaluated in immunocompromised people. Individuals with complement deficiencies and individuals with functional or anatomical asplenia may not mount an immune response to meningococcal group A, C, W-135 and Y conjugate vaccines.

Individuals with familial complement deficiencies (for example, C3 or C5 deficiencies) and individuals receiving treatments that inhibit terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by Neisseria meningitidis group A, C, W-135 and Y, even if they develop antibodies following vaccination with Menveo.

Thrombocytopenia and coagulation disorders

Menveo has not been evaluated in persons with thrombocytopenia, bleeding disorders or that are receiving anticoagulant therapy, because of the risk of haematoma. The risk-benefit ratio for persons at risk of haematoma following intramuscular injection must be evaluated by health care professionals.

Excipient with known effect

Sodium

This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodium-free’.

Drug interactions

SmPC 4.5 Interaction with other medicinal products and other forms of interaction EU SmPC (EMA)

Menveo can be given concomitantly with any of the following vaccines: monovalent and combined hepatitis A and B, yellow fever, typhoid fever (Vi polysaccharide), Japanese encephalitis, rabies and meningococcal group B (Bexsero).

In adolescents (11 to 18 years of age), Menveo has been evaluated in two co-administration studies with either Tetanus, Reduced Diphtheria and Acellular Pertussis Vaccine, adsorbed (Tdap) alone or Tdap and Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant (HPV), both of which support the co-administration of the vaccines.

The administration of Menveo one month after Tdap resulted in statistically significantly lower serogroup W-135 seroresponses. Since there was no direct impact on the seroprotection rate, the clinical consequences are presently unknown. There was evidence of some suppression of antibody

response to two of the three pertussis antigens. The clinical relevance of this observation is unknown. After vaccination, over 97% of subjects had detectable pertussis titers to all three pertussis antigens.

For children 2 to 10 years of age, no data are available for evaluating safety and immunogenicity of other childhood vaccines when administered concomitantly with Menveo.

Concomitant administration of Menveo with vaccines other than those listed above has not been studied. Concomitant vaccines should always be administered at separate injection sites and preferably contralateral. It should be checked if the adverse reactions may be intensified by any co-administration.

If a vaccine recipient is undergoing immunosuppressant treatment, the immunological response may be diminished.

Adverse reactions

SmPC 4.8 Undesirable effects EU SmPC (EMA)

Summary of the safety profile

The most frequently reported adverse reactions within 7 days after vaccination with a single dose of Menveo alone in individuals aged 2 years and above were injection-site pain (42.7%), headache (26.4%), injection-site erythema ≤ 50 mm (18.1%), malaise (17.3%), injection-site induration ≤ 50 mm (15.1%), myalgia (13.5%) and irritability (11.3%) in children aged 2 to 10 years. These adverse reactions were mostly mild or moderate in intensity.

Tabulated list of adverse reactions

The safety of Menveo in individuals aged 2 years and older was evaluated in 11 randomized studies. 12 775 individuals were included in the safety analyses, of these, 3 334 participants aged 2 to 10 years and 9 441 participants aged 11 to 65 years were exposed to Menveo in completed clinical studies.

The following adverse reactions, as listed in Table 1 below, have been identified in clinical studies conducted with Menveo when given to individuals 2 years and older, and during post-marketing surveillance.

Adverse reactions are listed below by MedDRA system organ class and frequency. Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness.

Very common      (≥ 1/10)
Common           (≥ 1/100 to < 1/10)
Uncommon         (≥ 1/1 000 to < 1/100)
Rare             (≥ 1/10 000 to < 1/1 000)
Very rare        (< 1/10 000)
Not known (cannot be estimated from the available data)

Table 1: Adverse reactions

System organ class              Frequency           Adverse reactions
Blood and lymphatic system
                                Uncommon            Lymphadenopathy1
disorders
Immune system disorders         Uncommon            Hypersensitivity1
                                Not known           Anaphylaxis1
Metabolism and nutrition
                                Common              Eating disorder2
disorders
Nervous system disorders        Very common         Headache
                                Common              Sleepiness2
                                Uncommon            Syncope1, dizziness3
                                Very rare           Tonic convulsion1, febrile convulsion1
Ear and labyrinth disorders     Uncommon            Vertigo1
Gastrointestinal disorders      Common              Vomiting2, diarrhoea2, nausea
Skin and subcutaneous tissue
                               Common               Rash
disorders
Musculoskeletal and            Very common        Myalgia
connective tissue disorders    Common             Arthralgia
General disorders and                             Irritability2, malaise, injection site pain, injection
administration site conditions Very common        site erythema (≤ 50 mm), injection site induration
                                                  (≤ 50 mm)
                                                  Fever (≥ 38 °C), chills, injection site erythema
                                Common
                                                  (> 50 mm), injection site induration (> 50 mm)
                                Uncommon          Injection site pruritus, injection site swelling1
                                                  injection site cellulitis1, extensive swelling of the
                                Very rare
                                                  injected limb1
  Adverse reaction reported during post-marketing surveillance
  Reported in children 2 to 10 years of age
  Reported in individuals 11 to 65 years of age

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

Pregnancy considerations

SmPC 4.6 Fertility, pregnancy and lactation EU SmPC (EMA)

Insufficient clinical data on exposed pregnancies are available.

In non-clinical studies, Menveo had no direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development. Considering the severity of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W-135 and Y, pregnancy should not preclude vaccination when the risk of exposure is clearly defined.

Although insufficient clinical data on the use of Menveo during breast-feeding are available, it is unlikely that secreted antibodies in milk would be harmful when ingested by a breastfed infant. Therefore, Menveo may be used during breast feeding.

Breastfeeding considerations

Breastfeeding is covered in SmPC 4.6 Fertility, pregnancy and lactation, under Pregnancy considerations above.

Overdose

SmPC 4.9 Overdose EU SmPC (EMA)

No case of overdose has been reported.

Mechanism of action

SmPC 5.1 Pharmacodynamic properties EU SmPC (EMA)

Pharmacotherapeutic group: Meningococcal vaccines, ATC code: J07AH08

Immunogenicity of Menveo liquid

Immunogenicity of Menveo liquid, as evaluated in a phase 2b observer-blind, randomised, multicentre, controlled clinical trial in subjects aged 10 to 40 years that assessed the non-inferiority for MenA of Menveo liquid (for the product aged 24 and 30 months) to Menveo lyophilised/liquid, is presented in Table 2.

Non-inferiority of Menveo liquid to Menveo lyophilised/liquid was demonstrated for MenA as per the 2 co-primary study endpoints (between groups ratio of geometric mean titers (GMTs) at 1-month post vaccination with formulation aged 24 and 30 months).

Table 2: Serum bactericidal antibody responses 1 month after vaccination in subjects aged 10-40 years receiving Menveo liquid or Menveo lyophilised/liquid formulation

   Study                                                                     Menveo            Menveo
  (Menveo                                                                    liquid /       liquid minus
                                       Menveo             Menveo
   liquid        Endpoint by                                                 Menveo            Menveo
                                    liquid (95%       lyophilised/liqu
  product         Serogroup                                               lyophilised/li    lyophilised/li
                                         CI)            id (95% CI)
    age)                                                                       quid          quid (95%
                                                                            (95% CI)             CI)
  V59_78               A              N = 363         N = 373
   (24                                 386.66
 months)**                                            318.34                  1.21
                     GMT              (319.47,                                                    -
                                                  (264.14, 383.67)        (0.94, 1.57)*
                                      467.97)
                                        93.65          92.19
                                                                                                1.46
                % hSBA ≥ 1:8       (90.70, 95.89)  (89.03, 94.67)                -
                                                                                            (-2.24, 5.22)
                                      N = 378         N = 384
                       C              N = 385         N = 377
                                       143.48
                                                      171.74                   0.84
                     GMT              (110.49,                                                    -
                                                  (131.74, 223.87)         (0.58, 1.19)
                                      186.30)
                                        77.58          78.01
                                                                                                -0.43
                % hSBA ≥ 1:8       (73.10, 81.63)  (73.52, 82.06)                -
                                                                                            (-6.32, 5.46)
                                      N = 388         N = 382
                    W-135             N = 372         N = 388
                                        62.63          66.37                   0.94
                     GMT                                                                          -
                                   (50.99, 76.92)  (54.26, 81.18)          (0.72, 1.24)
                                        79.43          80.87
                                                                                                -1.43
                % hSBA ≥ 1:8       (75.07, 83.34)  (76.62, 84.64)                -
                                                                                            (-7.05, 4.18)
                                      N = 389         N = 392
                       Y              N = 379         N = 390
                                       115.66         106.47                   1.09
                     GMT                                                                          -
                                  (94.13, 142.13) (86.93, 130.42)          (0.82, 1.44)
                                        87.50          85.46
                                                                                                2.04
                % hSBA ≥ 1:8       (83.77, 90.64)  (81.57, 88.80)                -
                                                                                            (-2.81, 6.90)
                                      N = 384         N = 392
  V59_78
                       A              N = 356             N = 349
    (30
  months)                              387.06
   ***                                                   348.89               1.11
                     GMT              (322.72,                                                    -
                                                     (290.09, 419.61)     (0.87, 1.42)*
                                      464.24)
                                        93.37              94.01
                                                                                                -0.64
                % hSBA ≥ 1:8       (90.37, 95.66)      (91.06, 96.21)            -
                                                                                            (-4.24, 2.96)
                                      N = 377             N = 367

                           C                N = 376                N = 377
                                             256.70
                                                                  226.09                   1.14
                        GMT                 (195.29,                                                              -
                                                              (171.62, 297.85)         (0.79, 1.64)
                                            337.41)
                                              84.17                82.85
                                                                                                               1.32
                  % hSBA ≥ 1:8           (80.10, 87.70)        (78.67, 86.51)                -
                                                                                                           (-3.99, 6.64)
                                            N = 379               N = 379
                       W-135                N = 374                N = 366
                                             83.23                 75.42                   1.10
                        GMT                                                                                       -
                                        (68.19, 101.60)        (61.56, 92.41)          (0.84, 1.45)
                                             85.86                 81.77
                                                                                                               4.09
                  % hSBA ≥ 1:8           (82.00, 89.17)        (77.54, 85.50)                -
                                                                                                           (-1.11, 9.33)
                                            N = 389               N = 384
                           Y                N = 386                N = 377
                                            112.38                117.56                   0.96
                        GMT                                                                                       -
                                        (91.56, 137.92)       (95.39, 144.89)          (0.72, 1.26)
                                             88.04                 87.56
                                                                                                               0.48
                  % hSBA ≥ 1:8           (84.42, 91.08)        (83.85, 90.69)                -
                                                                                                           (-4.16, 5.13)
                                            N = 393               N = 386
* Non-inferiority criterion met (the lower limit of the two-sided 95% CI > 0.5 for the between groups ratio of GMTs at
Day 29 [Menveo liquid / Menveo lyophilised/liquid]).
** refers to Part 1 of study V59_78, in which the Menveo liquid aged for 24 months was used.
*** refers to Part 2 of study V59_78, in which the Menveo liquid aged for 30 months was used.

Immunogenicity of Menveo lyophilised/liquid

The efficacy of Menveo has been inferred by measuring the production of serogroup-specific anti-capsular antibodies with bactericidal activity. Serum bactericidal activity (SBA) was measured using human serum as the source of exogenous complement (hSBA). The hSBA was the original correlate of protection against meningococcal disease.

Immunogenicity was evaluated in randomised, multicenter, active controlled clinical trials that enrolled children (2-10 years of age), adolescents (11-18 years of age), adults (19-55 years of age) and older adults (56-65 years of age).

Immunogenicity in children 2 to 10 years of age

In the pivotal study V59P20 immunogenicity of Menveo was compared to ACWY-D; 1 170 children were vaccinated with Menveo and 1 161 received the comparator vaccine in the per protocol populations. In two supportive studies V59P8 and V59P10 immunogenicity of Menveo was compared to ACWY-PS.

In the pivotal, randomised, observer-blind study V59P20, in which participants were stratified by age (2 through 5 years and 6 through 10 years), the immunogenicity of a single dose of Menveo one month post vaccination was compared with the single dose of ACWY-D. Immunogenicity results one month after Menveo vaccination among subjects aged 2-5 years and 6-10 years are summarised below in Table 3.

Table 3: Serum bactericidal antibody responses following Menveo one month after vaccination among subjects aged 2-5 years and 6-10 years

                                 2-5 years                                  6-10 years
Serogroup             hSBA ≥ 1:8          hSBA GMTs              hSBA ≥ 1:8          hSBA GMTs
                       (95% CI)            (95% CI)               (95% CI)             (95% CI)
       A                N = 606             N = 606                N = 551              N = 551
                          72%                 26                     77%                  35
                        (68, 75)            (22, 30)               (74, 81)             (29, 42)
       C                N = 607             N = 607                N = 554              N = 554
                          68%                 18                     77%                  36
                        (64, 72)            (15, 20)               (73, 80)             (29, 45)
  W-135                 N = 594             N = 594                N = 542              N = 542
                          90%                 43                     91%                  61
                        (87, 92)            (38, 50)               (88, 93)             (52, 72)
       Y                N = 593             N = 593                N = 545              N = 545
                          76%                 24                     79%                  34
                        (72, 79)            (20, 28)               (76, 83)             (28, 41)

In another randomised, observer-blind study (V59P8) US children were immunized with a single dose of either Menveo (N = 284) or ACWY-PS (N = 285). In the children 2-10 years of age, as well as in each age strata (2-5 and 6-10 years of age), immune response as measured by percentage of subjects with seroresponse, hSBA ≥ 1:8 and GMTs were not only non-inferior to comparator vaccine ACWY-PS, but all were statistically higher than the comparator for all serogroups and all immune measurements at 1 month post vaccination. At 1 year post vaccination, Menveo continued to be statistically higher than ACWY-PS for serogroups A, W-135 and Y, as measured by percentage of subjects with hSBA ≥ 1:8 and GMTs. Menveo was non-inferior on these endpoints for serogroup C (Table 4). The clinical relevance of higher post vaccination immune responses is not known.

Table 4: Immunogenicity of one dose of Menveo or ACWY-PS in subjects 2 through 10 years of age, measured at one month and twelve months post vaccination

                   1 month post vaccination                        12 months post vaccination
Sero          hSBA ≥ 1:8           hSBA GMTs                 hSBA ≥ 1:8             hSBA GMTs
grou            (95% CI)             (95% CI)                  (95% CI)               (95% CI)
 p                    ACWY                ACWY-                      ACWY
           Menveo              Menveo                     Menveo                Menveo ACWY-PS
                       -PS                    PS                       -PS
  A        N = 280 N = 281 N = 280 N = 281                N = 253 N = 238 N = 253            N = 238
                                             6.31                                3.88
             79%       37%        36                        23%        13%                      3
                                          (5.21, 7.6                           (3.39, 4.4
           (74, 84) (31, 43) (30, 44)                     (18, 29)    (9, 18)              (2.61, 3.44)
                                              4)                                   4)
  C        N = 281 N = 283 N = 281 N = 283                N = 252 N = 240 N = 252            N = 240
             73%       54%        26          15            53%        44%         11          9.02
           (68, 78) (48, 60) (21, 34)      (12, 20)       (47, 59) (38, 51) (8.64, 13) (7.23, 11)
 W-
           N = 279     N = 282    N = 279    N = 282      N = 249    N = 237    N = 249      N = 237
             92%         66%        60           14         90%        45%        42           7.57
           (88, 95)    (60, 71)   (50, 71)    (12, 17)    (86, 94)   (38, 51)   (35, 50)   (6.33, 9.07)
  Y        N = 280     N = 282    N = 280     N = 282     N = 250    N = 239    N = 250      N = 239
             88%         53%        54           11         77%        32%        27           5.29
           (83, 91)    (47, 59)   (44, 66)   (9.29, 14)   (71, 82)   (26, 38)   (22, 33)   (4.34, 6.45)

In a randomised, observer-blind study (V59P10) conducted in Argentina, children were immunized with a single dose of either Menveo (N = 949) or ACWY-PS (N = 551). Immunogenicity was assessed in a subset of 150 subjects in each vaccine group. The immune response observed in the children 2-10 years of age was very similar to those observed in the V59P8 study shown above:

immune response to Menveo at 1 month post vaccination, as measured by percentage of subjects with seroresponse, hSBA ≥ 1:8 and GMTs, was non-inferior to ACWY-PS.

A randomised, observer-blind study was conducted in children 12 to 59 months of age in Finland and Poland (V59P7). A total of 199 subjects 2-5 years of age were in the Menveo per protocol immunogenicity population and 81 subjects 3-5 years of age were in the ACWY-PS group.

At 1 month post-first vaccination, the percentages of subjects with hSBA ≥ 1:8 were consistently higher in the Menveo group for all four serogroups (63% vs 39%, 46% vs 39%, 78% vs 59%, and 65% vs 57% for Menveo as compared to ACWY-PS for serogroups A, C, W-135, and Y, respectively).

In a randomized, observer-blind study (V59_57) conducted in US, immunogenicity of a 2-dose series and a single dose of Menveo was compared in children 2 through 5 and 6 through 10 years of age (N = 715). At baseline, the percentage of subjects with hSBA ≥ 1:8 across the two age strata was 1%-5% for serogroup A, 13%-28% for serogroup C, 42%-64% for serogroup W-135, and 6%-19% for serogroup Y. At 1 month post last vaccination, the percentages of subjects with hSBA ≥ 1:8 in the 2-dose group and in the single dose group across the two age strata were: 90%-95% vs 76%-80% for serogroup A, 98%-99% vs 76%-87% for serogroup C, 99% vs 93%-96% for serogroup W-135, and 96% vs 65%-69% for serogroup Y. GMTs were higher in the 2-dose group than the single dose group at 1 month after vaccination in both age strata; however, this difference was less pronounced in the older age stratum.

At 1 year post last vaccination, the percentages of subjects with hSBA ≥ 1:8 after the 2-dose series and the single dose were both lower than at 1 month post vaccination (30% after the 2-dose series, 11%-20% after the single dose for serogroup A; 61%-81% and 41%-55% for serogroup C; 92%-94% and 90%-91% for serogroup W-135; 67%-75% and 57%-65% for serogroup Y). The differences between hSBA GMTs in the 2-dose and the single dose groups at 1 year after vaccination were lower than those seen at 1 month post vaccination.

The clinical benefit of a 2-dose vaccination series in children 2 through 10 years of age is not known.

Persistence of immune response and booster response in children 2 to 10 years of age

Antibody persistence at 5 years after primary vaccination was assessed in study V59P20E1, this was an extension of study V59P20. There was antibody persistence observed against serogroups C, W-135 and Y, with the percentages of subjects with hSBA ≥ 1:8 being 32% and 56% against serogroup C in subjects 2-5 and 6-10 years of age, respectively, 74% and 80% against serogroup W-135, and 48% and 53% against serogroup Y. GMTs were respectively 6.5 and 12 for serogroup C, 19 and 26 for serogroup W-135, and 8.13 and 10 for serogroup Y. For serogroup A, 14% and 22% of subjects 2-5 and 6-10 years of age, respectively, had hSBA ≥ 1:8 (GMTs 2.95 and 3.73). The children also received a booster dose of Menveo, 5 years after a single dose primary vaccination. All subjects in both age groups had hSBA ≥ 1:8 across all serogroups, with antibody titers several fold higher than seen after the primary vaccination (Table 5).

Table 5: Persistence of immune responses 5 years after primary vaccination with Menveo, and immune responses 1 month after a booster dose among subjects aged 2-5 years and 6-10 years at the time of primary vaccination

Serogr
                           2-5 years                                    6-10 years
 oup
                                    1 month after                                 1 month after
           5 year persistence                            5 year persistence
                                       booster                                       booster
            hSBA       hSBA       hSBA       hSBA        hSBA       hSBA        hSBA      hSBA
            ≥ 1:8      GMTs       ≥ 1:8     GMTs         ≥ 1:8      GMTs        ≥ 1:8     GMTs
            (95%       (95%       (95%       (95%        (95%       (95%        (95%       (95%
             CI)        CI)        CI)        CI)         CI)        CI)         CI)        CI)

   A        N = 96     N = 96     N = 95     N = 95      N = 64     N = 64     N = 60      N = 60
                        2.95      100%         361                   3.73      100%          350
             14%                                           22%
                       (2.42,      (96,       (299,                 (2.74,      (94,        (265,
            (7, 22)                                      (13, 34)
                       3.61)       100)       436)                  5.06)       100)        463)
   C        N = 96     N = 96     N = 94     N = 94      N = 64     N = 64     N = 60      N = 60
                        6.5       100%         498                    12       100%          712
             32%                                           56%
                       (4.75,      (96,       (406,                 (7.72,      (94,        (490,
           (23, 43)                                      (43, 69)
                        8.9)       100)       610)                   19)        100)       1 036)
W-135       N = 96     N = 96     N = 95     N = 95      N = 64     N = 64     N = 60      N = 60
                                  100%        1 534                            100%         1 556
             74%         19                                80%        26
                                   (96,      (1 255,                            (94,       (1 083,
           (64, 82)    (14, 25)                          (68, 89)   (18, 38)
                                   100)      1 873)                             100)       2 237)
   Y        N = 96     N = 96     N = 94     N = 94      N = 64     N = 64     N = 59      N = 59
                        8.13      100%        1 693                   10       100%         1 442
             48%                                           53%
                       (6.11,      (96,      (1 360,                (6.51,      (94,       (1 050,
           (38, 58)                                      (40, 66)
                        11)        100)      2 107)                  16)        100)       1 979)

Immunogenicity in individuals 11 years of age and above

In the pivotal study (V59P13), adolescents and adults received either a dose of Menveo (N = 2 649) or the comparator vaccine ACWY-D (N = 875). Sera were obtained both before vaccination and 1 month after vaccination.

In another study (V59P6) conducted in 524 adolescents, the immunogenicity of Menveo was compared to that of ACWY-PS.

Immunogenicity in adolescents

In the 11-18 year-old population of the pivotal study, V59P13, the immunogenicity of a single dose of Menveo one month post vaccination is compared with the ACWY-D. Immunogenicity results at one month after Menveo are summarised below in Table 6.

Table 6: Serum bactericidal antibody responses following Menveo one month after vaccination among subjects aged 11-18 years

                                                    GMT                     hSBA ≥ 1:8
Serogroup                    N
                                                  (95% CI)                   (95% CI)
   A                       1 075                  29 (24, 35)               75% (73, 78)
   C                       1 396                  50 (39, 65)               85% (83, 87)
  W-135                    1 024                 87 (74, 102)               96% (95, 97)
   Y                       1 036                  51 (42, 61)               88% (85, 90)

In the subset of subjects aged 11-18 years who were seronegative at baseline (hSBA < 1:4), the proportion of subjects who achieved a hSBA ≥ 1:8 after a dose of Menveo were as follows: serogroup A 75% (780/1 039); serogroup C 80% (735/923); serogroup W-135 94% (570/609); serogroup Y 81% (510/630).

In the non-inferiority study, V59P6, immunogenicity was assessed among adolescents aged 11-17 years who had been randomised to receive either Menveo or ACWY-PS. Menveo was shown to be non-inferior to ACWY-PS vaccine for all four serogroups (A, C, W-135 and Y) based on seroresponse, proportions achieving hSBA ≥ 1:8, and GMTs (Table 7).

Table 7: Immunogenicity of one dose of Menveo or ACWY-PS in adolescents, measured at one month post vaccination

                              hSBA ≥ 1:8                                 hSBA GMTs
Serogroup                      (95% CI)                                   (95% CI)
                     Menveo             ACWY-PS                Menveo            ACWY-PS
     A               N = 140             N = 149                N = 140            N = 149
                       81%                 41%                    33                 7.31
                     (74, 87)            (33, 49)               (25, 44)         (5.64, 9.47)
     C               N = 140             N = 147                N = 140            N = 147
                       84%                 61%                    59                  28
                     (77, 90)            (53, 69)               (39, 89)           (19, 41)
  W-135              N = 138             N = 141                N = 138            N = 141
                       91%                 84%                    48                  28
                     (84, 95)            (77, 89)               (37, 62)           (22, 36)
     Y               N = 139             N = 147                N = 139            N = 147
                       95%                 82%                    92                  35
                     (90, 98)            (75, 88)              (68, 124)           (27, 47)

At one year post vaccination in these same subjects, compared with ACWY-PS, a higher proportion of subjects vaccinated with Menveo had hSBA ≥ 1:8 for serogroups C, W-135, and Y, with comparable levels for serogroup A. Similar findings were observed in the comparison of hSBA GMTs.

Persistence of immune response and booster response in adolescents

In study V59P13E1, the persistence of immune responses against serogroups A, C, W-135 and Y was assessed at 21 months, 3 years and 5 years post primary vaccination among subjects aged 11-18 years at the time of vaccination. The percentages of subjects with hSBA ≥ 1:8 remained constant against serogroups C, W-135, and Y from 21 months to 5 years post vaccination in the Menveo group and decreased slightly over time against serogroup A (Table 8). At 5 years after primary vaccination, there

were significantly higher percentages of subjects with hSBA ≥ 1:8 in the Menveo group than in the vaccine-naive control subjects against all the four serogroups.

Table 8: Persistence of immune responses approximately 21 months, 3 years and 5 years after vaccination with Menveo (subjects were aged 11-18 years at the time of vaccination)

                                       Percentages of subjects with
                                                                             hSBA GMTs
Serogroup           Timepoint                  hSBA ≥ 1:8
                                                Menveo                          Menveo
                                                N = 100                         N = 100
                                                    45                      6.57 (4.77-9.05)
                     21 months
                                                 (35, 55)
     A                                              38                      5.63 (3.97-7.99)
                      3 years
                                                 (28, 48)
                                                    35                      4.43 (3.13-6.26)
                      5 years
                                                 (26, 45)
                                                N = 100                         N = 100
                                                    61                        11 (8.12-15)
                     21 months
                                                 (51, 71)
     C                                              68                         16 (11-25)
                      3 years
                                                 (58, 77)
                                                    64                        14 (8.83-24)
                      5 years
                                                 (54, 73)
                                                  N = 99                        N = 99
                                                    86                         18 (14-25)
                     21 months
                                                 (77, 92)
  W-135                                             85                         31 (21-46)
                      3 years
                                                 (76, 91)
                                                    85                         32 (21-47)
                      5 years
                                                 (76, 91)
                                                N = 100                         N = 100
                                                    71                         14 (10-19)
                     21 months
                                                 (61, 80)
     Y                                              69                        14 (9.68-20)
                      3 years
                                                 (59, 78)
                                                    67                         13 (8.8-20)
                      5 years
                                                 (57, 76)

A booster dose of Menveo was administered 3 years after primary vaccination with Menveo or ACWY-D. Both groups showed a robust response to the booster dose of Menveo at one month after vaccination (100% of subjects had hSBA ≥ 1:8 across serogroups) and this response largely persisted through 2 years after the booster dose for serogroups C, W-135 and Y (with 87% to 100% of subjects with hSBA ≥ 1:8 across serogroups). A small decline was observed in percentages of subjects with hSBA ≥ 1:8 against serogroup A, although percentages were still high (77% to 79%). GMTs declined over time as expected but remained between 2- and 8-fold higher than prebooster values (Table 10).

In study V59P6E1, at one year post vaccination, the percentage of Menveo recipients with hSBA ≥ 1:8 remained significantly higher compared with ACWY-PS recipients for serogroups C, W-135 and Y, and similar between the two study groups for serogroup A. hSBA GMTs for serogroups W-135 and Y were higher among Menveo recipients. In 5 years post vaccination, the percentage of Menveo recipients with hSBA ≥ 1:8 remained significantly higher compared with ACWY-PS recipients for serogroups C and Y. Higher hSBA GMTs were observed for serogroups W-135 and Y (Table 9).

Table 9: Persistence of immune responses approximately 12 months and 5 years after vaccination with Menveo and ACWY-PS (subjects were aged 11-18 years at the time of vaccination)

                            Percentages of subjects with
                                                                              hSBA GMTs
                                    hSBA ≥ 1:8
                                                P Value                                       P Value
Serogroup     Timepoint                         Menveo                                        Menveo
                                     ACWY-
                            Menveo                  vs           Menveo        ACWY-PS           vs
                                        PS
                                                ACWY-                                         ACWY-
                                                   PS                                           PS
                            N = 50    N = 50                      N = 50         N = 50
                                                                   5.19
                              41%        43%                                       6.19
               12 months                                0.73    (3.34, 8.09                    0.54
                            (27, 56)   (28, 59)                                (3.96, 9.66)
     A                                                               )
                                                                   5.38
                              30%        44%                                      7.75
                5 years                                 0.15    (3.29, 8.78                    0.24
                            (18, 45)   (30, 59)                                (4.83, 12)
                                                                     )
                             N = 50     N = 50                    N = 50         N = 50
                              82%        52%                        29             17
               12 months                               <0.001                                  0.22
     C                      (68, 91)   (37, 68)                  (15, 57)      (8.55, 33)
                              76%        62%                        21             20
                5 years                                0.042                                   0.92
                            (62, 87)   (47, 75)                  (12, 37)       (12, 35)
                             N = 50     N = 50                    N = 50         N = 50
                              92%        52%                        41             10
               12 months                               <0.001                                 <0.001
  W-135                     (80, 98)   (37, 68)                  (26, 64)      (6.41, 16)
                              72%        56%                        30             13
                5 years                                0.093                                   0.012
                            (58, 84)   (41, 70)                  (18, 52)      (7.65, 22)
                             N = 50     N = 50                    N = 50         N = 50
                              78%        50%                        34            9.28
               12 months                               0.001                                  <0.001
     Y                      (63, 88)   (35, 65)                  (20, 57)       (5.5, 16)
                              76%        50%                        30            8.25
                5 years                                0.002                                  <0.001
                            (62, 87)   (36, 64)                  (18, 49)      (5.03, 14)

A booster dose of Menveo was administered 5 years after primary vaccination with Menveo or ACWY-PS. At 7 days after the booster dose, 98%-100% of subjects who previously received Menveo and 73%-84% of subjects who previously received ACWY-PS achieved hSBA ≥ 1:8 against serogroups A, C, W-135 and Y. At one month post vaccination, the percentages of subjects with hSBA ≥ 1:8 were 98%-100% and 84%-96%, respectively.

A significant increase in the hSBA GMTs against all four serogroups was also observed at 7 and 28 days after the booster dose (Table 10).

Table 10: Response to Booster: bactericidal antibody responses to Menveo booster administered at 3 or 5 years after the primary vaccination with Menveo or ACWY-PS in subjects aged 11-17 years

                      Percentages of subjects with
                                                                       hSBA GMTs
                              hSBA ≥ 1:8
                   V59P13E
                                                        V59P13E1
                                      V59P6E1            (3 years              V59P6E1
Serog     Time     (3 years
                                    (5 years post          post              (5 years post
roup      point       post
                                    vaccination)        vaccinatio           vaccination)
                   vaccinati
                                                            n)
                      on)
                                             ACWY-                                      ACWY-
                   Menveo      Menveo                    Menveo          Menveo
                                                PS                                         PS
                     N = 42      N = 49       N = 49      N = 42           N = 49        N = 49
         Pre-boo      21%         29%          43%          2.69            5.16          7.31
           ster     (10, 37)    (17, 43)     (29, 58)   (1.68, 4.31)     (3.46, 7.7)   (4.94, 11)
                                 100%          73%                         1 059           45
         7 days        -                                     -
  A                            (93, 100)     (59, 85)                   (585, 1 917)    (25, 80)
                     100%         98%          94%         326              819           147
         28 days
                   (92, 100) (89, 100)       (83, 99)   (215, 494)      (514, 1305)    (94, 232)
                      79%                                   22
         2 years                   -             -                           -               -
                    (63, 90)                             (12, 41)
                     N = 42      N = 49       N = 49      N = 42           N = 49       N = 49
         Pre-boo      55%         78%          61%          16               20           19
           ster     (39, 70)    (63, 88)     (46, 75)   (8.66, 31)        (13, 33)     (12, 31)
                                 100%          78%                         1 603          36
         7 days        -                                     -
                               (93, 100)     (63, 88)                   (893, 2 877)   (20, 64)
  C
                     100%        100%         84%                          1 217         51
         28 days                                        (352, 1 014
                   (92, 100)   (93, 100)    (70, 93)                    (717, 2 066)   (30, 86)
                                                              )
                      95%                                   124
         2 years                   -               -                         -               -
                    (84, 99)                             (62, 250)
                     N = 41      N = 49      N = 49        N = 41          N = 49       N = 49
         Pre-boo      88%         73%         55%            37              29            12
           ster     (74, 96)    (59, 85)    (40, 69)      (21, 65)        (17, 49)     (7.02, 19)
                                                                           1 685
                                 100%         84%                                        34
         7 days        -                                     -         (1 042, 2 725
                               (93, 100)    (70, 93)                                   (21, 54)
W-135                                                                         )
                                                            673            1 644
                     100%        100%         92%                                        47
         28 days                                        (398, 1 137    (1 090, 2 481
                   (91, 100)   (93, 100)    (80, 98)                                   (32, 71)
                                                              )               )
                     100%                                    93
         2 years                   -               -                         -
                   (91, 100)                             (58, 148)
                     N = 42      N = 49      N = 49       N = 42           N = 49       N = 49
         Pre-boo      74%         78%         51%            14              28           7.8
           ster     (58, 86)    (63, 88)    (36, 66)     (8.15, 26)       (18, 45)     (4.91, 12)
                                                                           2 561
                                 98%          76%                                        21
         7 days        -                                     -         (1 526, 4 298
                               (89, 100)    (61, 87)                                   (13, 35)
  Y                                                                           )
                                                                           2 092
                     100%        100%         96%          532                           63
         28 days                                                       (1 340, 3 268
                   (92, 100)   (93, 100)    (86, 100)   (300, 942)                     (41, 98)
                                                                              )
                      95%                                   55
         2 years                   -               -                         -               -
                    (84, 99)                             (30, 101)

Immunogenicity in adults

In the pivotal immunogenicity trial, V59P13, immune responses to Menveo were assessed among adults aged 19 to 55 years. Results are presented in Table 11. In the subset of subjects aged 19-55 years who were seronegative at baseline, the proportion of subjects who achieved a hSBA ≥ 1:8 after a dose of Menveo were as follows: serogroup A 67% (582/875); serogroup C 71% (401/563); serogroup W-135 82% (131/160); serogroup Y 66% (173/263).

Table 11: Serum bactericidal antibody responses following Menveo one month after vaccination among subjects aged 19-55 years

                                                 GMT                      hSBA ≥ 1:8
Serogroup                N
                                               (95% CI)                    (95% CI)
   A                    963                    31 (27, 36)                69% (66, 72)
   C                    902                    50 (43, 59)                80% (77, 83)
  W-135                 484                   111 (93, 132)               94% (91, 96)
   Y                    503                    44 (37, 52)                79% (76, 83)

The onset of immune response after the primary vaccination with Menveo in healthy subjects 18 through 22 years of age was evaluated in study V59P6E1. At 7 days post vaccination, 64% of subjects achieved hSBA ≥ 1:8 against serogroup A and 88% through 90% of subjects had bactericidal antibodies against serogroups C, W-135 and Y. At one month post vaccination, 92% through 98% of subjects had hSBA ≥ 1:8 against serogroups A, C, W-135 and Y. A robust immune response as measured by hSBA GMTs against all serogroups was also observed at 7 days (GMTs 34 through 70) and 28 days (GMTs 79 through 127) after a single dose vaccination.

Immunogenicity in older adults (aged 56-65 years)

The comparative immunogenicity of Menveo vs. ACWY-PS was evaluated in subjects aged 56-65 years, in study V59P17. The proportion of subjects with hSBA ≥ 1:8 was non-inferior to ACWY-PS for all four serogroups and statistically superior for serogroups A and Y (Table 12).

Table 12: Immunogenicity of one dose of Menveo or ACWY-PS in adults aged 56-65 years, measured at one month post vaccination.

                                   Menveo                           ACWY-PS
Serogroup                        hSBA ≥ 1:8                         hSBA ≥ 1:8
                                  (95% CI)                           (95% CI)
                                    N = 83                             N = 41
      A                              87%                                63%
                                   (78, 93)                           (47, 78)
                                    N = 84                             N = 41
      C                              90%                                83%
                                   (82, 96)                           (68, 93)
                                    N = 82                             N = 39
  W-135                              94%                                95%
                                   (86, 98)                           (83, 99)
                                    N = 84                             N = 41
      Y                              88%                                68%
                                   (79, 94)                           (52, 82)

Available data in children 2 to 23 months of age

The immunogenicity of Menveo in children 2 to 23 months of age was evaluated in several studies. Although a high percentage of subjects achieved hSBA titers above 1:8 following 4-dose series of Menveo, with lower percentages in studies of 2-dose series and of a single dose, Menveo was

compared to another meningococcal vaccine in only one pivotal study, where it failed to show a response at least equivalent to a monovalent conjugated serotype C vaccine (after a single dose at the age of 12 months). Currently available data are not sufficient to establish the efficacy of Menveo in children under 2 years of age. See section 4.2 for information on paediatric use.

Pharmacokinetics

SmPC 5.2 Pharmacokinetic properties EU SmPC (EMA)

Not applicable.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. European Medicines Agency. Menveo: EPAR, product information, Annex I, Summary of Product Characteristics [EU SmPC, last updated October 14, 2025; no US FDA label]. https://www.ema.europa.eu/en/medicines/human/EPAR/menveo © European Medicines Agency; reproduced with acknowledgment of the source.
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .